Oral nucleos (t) ide analogues (NAs) is one of the main and efficient way for the treatment of chronic hepatitis B (CHB) . Considering the antiviral potency and drug resistance of domestic and foreign guidelines, NAs are divided into first-line and non-first-line drugs. “An Expert Consensus for the Adjustment of Treatment Strategies in Patients with Chronic Hepatitis B Treated with Non-first-line Nucleos (t) ide Analogues, ”is mainly aimed at those patients who are currently using non-first-line NAs drugs. In addition, how to standardize the adjustment to first-line NAs drugs of choice, which can strengthen the effectiveness of initial antiviral treatment to obtain better antiviral efficacy, and improve patient compliance, coinciding with the avoidance of occurrence of serious drug adverse reactions in patients with CHB is presented.
[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
[2]European Association for the Study of the Liver.EASL 2017clinical practice guidelines on the management of hepatitis Bvirus infection[J].J Hepatol, 2017, 67 (2) :370-398.
|
[3] TERRAULT NA, LOK AS, McMAHON BJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD2018 hepatitis B guidance[J].Hepatology, 2018, 67 (4) :1560-1599.
|
[4]World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M].Geneva:World Health Organization, 2015.
|
[5]YU R, FAN R, HOU JL.Chronic hepatitis B virus infection:Epidemiology, prevention, and treatment in China[J].Front Med, 2014, 8 (2) :135-144.
|
[6]LOK AS, TRINH H, CAROSI G, et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos (t) ide-na6ve patients with chronic hepatitis B[J].Gastroenterology, 2012, 143 (3) :619-628.e1.
|
[7]AGARWAL K, BRUNETTO M, SETO WK, et al.96 weeks treatment of tenofovir alafenamide vs.tenofovir disoproxil fumarate for hepatitis B virus infection[J].J Hepatol, 2018, 68 (4) :672-681.
|
[8]BRUNETTO M, LIM YS, GANE E, et al.A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBe Ag-negative, chronic hepatitis B (CHB) :Efficacy and safety results at week 96[J].JHepatol, 2017, 66 (Suppl 1) :s25-s26.
|
[9]GU EL, YU YQ, WANG JL, et al.Response-guided treatment of cirrhotic chronic hepatitis B patients:Multicenter prospective study[J].World J Gastroenterol, 2015, 21 (2) :653-660.
|
[10]CHOI J, KIM H J, LEE J, et al.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B:A Korean nationwide cohort study[J].JAMA Oncol, 2019, 5 (1) :30-36.
|
[11]FASANO M, LAMPERTICO P, MARZANO A, et al.HBV DNAsuppression and HBsAg clearance in HBe Ag negative chronic hepatitis B patients on lamivudine therapy for over 5 years[J].J Hepatol, 2012, 56 (6) :1254-1258.
|
[12]YU Y, WANG J, LI G, et al.Nucleos (t) ide analogue interruption:Alternative approach to intrahepatic set point for spontaneous control of HBV replication?[J].J Hepatol, 2018, 68 (3) :609-610.
|